CLARUS THERAPEUTICS, INC.

Patent Trials and Appeals Board

Jul 26, 2021

106128 (P.T.A.B. Jul. 26, 2021)

BoxInterferences@uspto.gov Filed: July 26, 2021
Tel: 571-272-9797

UNITED STATES PATENT AND TRADEMARK OFFICE
_______________

BEFORE THE PATENT TRIAL AND APPEAL BOARD
______________

CLARUS THERAPEUTICS, INC.
(Inventors: Robert E. Dudley and Panayiotis P. Constantinides)
Junior Party
(Patent Application 16/656,178).
v.

LIPOCINE, INC.
(Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram,
Mahesh V. Patel and Srinivasan Venkateshwaran)

Senior Party
(Patent Application 16/818,779),

Patent Interference No. 106,128 (DK)
(Technology Center 1600)

Judgment
37 C.F.R. § 41.127(b)

Before, SALLY GARDNER LANE, JAMES T. MOOORE, and DEBORAH
KATZ, Administrative Patent Judge.

KATZ, Administrative Patent Judge.

Senior Party Lipocine, Inc. (“Lipocine”) requests adverse judgment. (See 1
Paper 108.) The request for adverse judgment is GRANTED. Accordingly, we 2
enter judgment against Lipocine. 3
Interference 106,128

-2-
It is 1
ORDERED that judgment on priority is entered against Lipocine as to Count 2
1, the sole Count of the interference (see Declaration, Paper 1, 4–5); 3
FURTHER ORDERED that claims 32–42 of Lipocine application 4
16/818,779, which correspond to Count 1, are finally refused; (see Declaration, 5
Paper 1, 5; 35 U.S.C. § 135(a);1 6
FURTHER ORDERED that the parties are directed to 35 USC § 135(c) and 7
37 C.F.R. § 41.205 regarding the filing of settlement agreements; 8
FURTHER ORDERED that a party seeking judicial review timely serve 9
notice on the Director of the United States Patent and Trademark Office; 37 C.F.R. 10
§§ 90.1 and 104.2. See also 37 C.F.R. § 41.8(b). Attention is directed to Biogen 11
Idec MA, Inc., v. Japanese Foundation for Cancer Research, 785 F.3d 648, 654–57 12
(Fed. Cir. 2015) (determining that pre-AIA § 146 review was eliminated for 13
interference proceedings declared after September 15, 2012); and 14
FURTHER ORDERED that a copy of this judgment be entered into the 15
administrative records of Junior Party Clarus Therapeutics, Inc. 16
application 16/656,178 and Lipocine application 16/818,779. 17

1 Patent interferences continue under the relevant statutes in effect on
15 March 2013. See Pub. L. 112-29, § 3(n), 125 Stat. 284, 293 (2011).
Interference 106,128

-3-
cc (via e-mail): 1
Attorney for Junior Party CLARUS 2
Daniel J. Pereira 3
OBLON, McCLELLAND, 4
MAIER & NEUSTADT, L.L.P. 5
int106128@oblon.com 6
7
Christopher T Griffith 8
GREEN, GRIFFITH & BORG-BREEN LLP 9
cgriffith@greengriffith.com 10
11
Dennis Bennett 12
GLOBAL PATENT GROUP 13
dbennett@globalpatentgroup.com 14
15
Attorney for Senior Party LIPOCINE 16
17
Marc Wefers 18
Chris Bowley 19
Geoffrey D. Biegler 20
FISH & RICHARDSON P.C. 21
wefers@fr.com 22
bowley@fr.com 23
biegler@fr.com 24
25